CA2006929A1 - Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs - Google Patents
Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogsInfo
- Publication number
- CA2006929A1 CA2006929A1 CA002006929A CA2006929A CA2006929A1 CA 2006929 A1 CA2006929 A1 CA 2006929A1 CA 002006929 A CA002006929 A CA 002006929A CA 2006929 A CA2006929 A CA 2006929A CA 2006929 A1 CA2006929 A1 CA 2006929A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- polypeptides
- binding domain
- dna encoding
- polypeptide analogs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 13
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 13
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000010367 cloning Methods 0.000 title 1
- 102000009123 Fibrin Human genes 0.000 abstract 3
- 108010073385 Fibrin Proteins 0.000 abstract 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 3
- 229950003499 fibrin Drugs 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 102000007562 Serum Albumin Human genes 0.000 abstract 1
- 108010071390 Serum Albumin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 229960000182 blood factors Drugs 0.000 abstract 1
- -1 blood factors Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Anesthesiology (AREA)
- Physics & Mathematics (AREA)
Abstract
This invention provides plasmids for bacterial expression of polypeptides which comprise a substantial portion of the amino acid sequence of, and which have the biological activity of, one of the domains of naturally-occurring human fibronectin, such as the cell binding domain or fibrin binding domain, comprising DNA encoding the polypeptide and DNA encoding suitable regulatory elements positioned relative to the DNA encoding the polypeptide so as to effect expression of the polypeptide in a suitable host cell. In the presently preferred embodiments of the invention, the polypeptide is a 75 kD, 40 kD or 33 kD polypeptide of the cell binding domain, or a 31 kD or 20 kD polypeptide of the fibrin binding domain. The invention also provides methods for producing the polypeptides and pharmaceutical compositions comprising the polypeptides and pharmaceutically acceptable carriers. The polypeptides of this invention may be used to inhibit platelet aggregation, to inhibit thromboxane release from platelets, or to treat a subject with a cerebrovascular disorder, a cardiovascular disorder, a wound, a bacterial infection, a cancer, or to detect a fibrin thrombi. The invention further provides the polypeptides conjugated to thrombolytic agents, growth factors, serum albumin, blood factors, or polyethyleneglycol.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/259,569 US5679320A (en) | 1988-12-29 | 1994-06-14 | Fibrin binding domain polypeptides and uses and methods of producing same |
| US08/409,750 US5965383A (en) | 1988-12-29 | 1995-03-24 | Fibrin binding domain polypeptides and uses and methods of producing same |
| US08/826,885 US5869616A (en) | 1988-12-29 | 1997-04-08 | Fibrin binding domain polypeptides and uses and methods of producing same |
| US08/909,140 US6121426A (en) | 1988-12-29 | 1997-08-11 | Fibrin binding domain polypeptides and uses and methods of producing same |
| US09/492,971 US7087722B1 (en) | 1988-12-29 | 2000-01-27 | Fibrin binding domain polypeptides and uses and methods of producing same |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29195188A | 1988-12-29 | 1988-12-29 | |
| US291,915 | 1988-12-29 | ||
| US34595289A | 1989-04-28 | 1989-04-28 | |
| US345,952 | 1989-04-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2006929A1 true CA2006929A1 (en) | 1990-06-29 |
| CA2006929C CA2006929C (en) | 2005-10-18 |
Family
ID=26967068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002006929A Expired - Lifetime CA2006929C (en) | 1988-12-29 | 1989-12-29 | Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0451211A4 (en) |
| JP (1) | JP3095771B2 (en) |
| KR (1) | KR910700339A (en) |
| AU (1) | AU636596B2 (en) |
| CA (1) | CA2006929C (en) |
| DK (2) | DK128091A (en) |
| IL (1) | IL92925A0 (en) |
| WO (1) | WO1990007577A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270030A (en) * | 1988-12-29 | 1993-12-14 | Bio-Technology General Corp. | Fibrin binding domain polypeptide and method of producing |
| US5792742A (en) * | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
| GB9401689D0 (en) * | 1994-01-28 | 1994-03-23 | Univ Manchester | Diagnosis and treatment of endocarditis |
| EP3671511B1 (en) | 2018-12-19 | 2022-07-06 | Rohde & Schwarz GmbH & Co. KG | Communication system and method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516421D0 (en) * | 1985-06-28 | 1985-07-31 | Biotechnology Interface Ltd | Fibronectins |
-
1989
- 1989-12-29 CA CA002006929A patent/CA2006929C/en not_active Expired - Lifetime
- 1989-12-29 EP EP19900902086 patent/EP0451211A4/en not_active Withdrawn
- 1989-12-29 KR KR1019900701929A patent/KR910700339A/en active IP Right Grant
- 1989-12-29 IL IL92925A patent/IL92925A0/en unknown
- 1989-12-29 WO PCT/US1989/005875 patent/WO1990007577A1/en not_active Application Discontinuation
- 1989-12-29 JP JP02502804A patent/JP3095771B2/en not_active Expired - Lifetime
- 1989-12-29 AU AU49598/90A patent/AU636596B2/en not_active Expired
-
1991
- 1991-06-28 DK DK128091A patent/DK128091A/en not_active Application Discontinuation
-
1993
- 1993-01-18 DK DK9356A patent/DK5693D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK128091A (en) | 1991-08-29 |
| EP0451211A4 (en) | 1992-09-09 |
| KR910700339A (en) | 1991-03-14 |
| DK5693A (en) | 1993-01-18 |
| EP0451211A1 (en) | 1991-10-16 |
| JPH04505698A (en) | 1992-10-08 |
| AU4959890A (en) | 1990-08-01 |
| WO1990007577A1 (en) | 1990-07-12 |
| JP3095771B2 (en) | 2000-10-10 |
| DK5693D0 (en) | 1993-01-18 |
| DK128091D0 (en) | 1991-06-28 |
| CA2006929C (en) | 2005-10-18 |
| AU636596B2 (en) | 1993-05-06 |
| IL92925A0 (en) | 1990-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nachman et al. | Characterization of human platelet vascular permeability-enhancing activity | |
| EP0319506B1 (en) | Novel platelet-aggregation inhibitor peptide derivatives | |
| EP0259475A4 (en) | Recombinant human endothelial cell growth factor. | |
| ZA943464B (en) | Vascular endothelial growth factor 2 | |
| DK601786A (en) | HIS UNKNOWN PROCOAGULATION PROTEINS | |
| CA2149319A1 (en) | Haemophilus outer membrane protein | |
| KR950003492B1 (en) | Thrombus control agent | |
| ES8800347A1 (en) | Method for preparing protease-resistant single-chain urokinase | |
| HK1000968A1 (en) | A polypeptide capable of interacting with thrombin | |
| HU895788D0 (en) | Process for producing peptides and medical products containing them | |
| CA2006929A1 (en) | Cloning and production of polypeptide analogs of human fibronectin and methods of using such polypeptide analogs | |
| HUT50195A (en) | New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions | |
| DE3689921D1 (en) | Human placental angiogenic factor, suitable for the stimulation of capillary synthesis, endothelial cell protease, DNA synthesis and colonization. | |
| IL90134A (en) | Recombinant dna molecule encoding for plasmodium falciparum surface protein of zygotes and ookinetes and pharmaceutical compositions containing said protein prepared by expressing said dna | |
| AU674061B2 (en) | Factor XIII for treatment of skin wounds | |
| ATE108833T1 (en) | ANTIBODIES AGAINST FIBRIN, IMMUNOGENIC PEPTIDES FOR THE PRODUCTION OF THESE ANTIBODIES, METHODS FOR THE DETERMINATION OF FIBRIN AND PHARMACEUTICAL PREPARATIONS BASED ON THESE ANTIBODIES. | |
| AU1321988A (en) | The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein | |
| CA2159609C (en) | Factor xiii for treatment of skin wounds | |
| IT8548379A0 (en) | HYDRAZIDES OF PYRRIBENZOIC AND PYRRILACETIC ACIDS WITH ANTIAMINOOXIDASIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |